CN116549437A - 大麻素类和n-酰基乙醇胺的组合 - Google Patents

大麻素类和n-酰基乙醇胺的组合 Download PDF

Info

Publication number
CN116549437A
CN116549437A CN202310678191.6A CN202310678191A CN116549437A CN 116549437 A CN116549437 A CN 116549437A CN 202310678191 A CN202310678191 A CN 202310678191A CN 116549437 A CN116549437 A CN 116549437A
Authority
CN
China
Prior art keywords
certain embodiments
cannabinoid
pharmaceutical composition
salt
thc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310678191.6A
Other languages
English (en)
Chinese (zh)
Inventor
A·施穆勒维茨
E·哈勃
E·布雷纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurotherapy Laboratory Co
Original Assignee
Sespak Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sespak Co ltd filed Critical Sespak Co ltd
Publication of CN116549437A publication Critical patent/CN116549437A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyrane Compounds (AREA)
CN202310678191.6A 2015-04-29 2016-04-19 大麻素类和n-酰基乙醇胺的组合 Pending CN116549437A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562154144P 2015-04-29 2015-04-29
US62/154,144 2015-04-29
CN201680024534.5A CN107530317A (zh) 2015-04-29 2016-04-19 大麻素类和n‑酰基乙醇胺的组合
PCT/IL2016/050414 WO2016174661A1 (en) 2015-04-29 2016-04-19 Combinations of cannabinoids and n-acylethanolamines

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680024534.5A Division CN107530317A (zh) 2015-04-29 2016-04-19 大麻素类和n‑酰基乙醇胺的组合

Publications (1)

Publication Number Publication Date
CN116549437A true CN116549437A (zh) 2023-08-08

Family

ID=57199061

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202310678191.6A Pending CN116549437A (zh) 2015-04-29 2016-04-19 大麻素类和n-酰基乙醇胺的组合
CN201680024534.5A Pending CN107530317A (zh) 2015-04-29 2016-04-19 大麻素类和n‑酰基乙醇胺的组合

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201680024534.5A Pending CN107530317A (zh) 2015-04-29 2016-04-19 大麻素类和n‑酰基乙醇胺的组合

Country Status (12)

Country Link
US (7) US11234956B2 (enExample)
EP (2) EP3288553B1 (enExample)
JP (2) JP6938465B2 (enExample)
CN (2) CN116549437A (enExample)
AU (3) AU2016254685B2 (enExample)
CA (1) CA2984088C (enExample)
DK (1) DK3288553T3 (enExample)
ES (1) ES2935605T3 (enExample)
IL (2) IL291864A (enExample)
MA (1) MA41997A (enExample)
PL (1) PL3288553T3 (enExample)
WO (1) WO2016174661A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3288553T3 (pl) * 2015-04-29 2023-03-20 Scisparc Ltd Połączenia kannabinoidów i n-acyloetanoloamin
WO2019136351A1 (en) * 2018-01-05 2019-07-11 Altus Labs, Llc Personal care compositions
CA3126772A1 (en) * 2018-01-29 2019-08-01 Evero Compositions and methods for treating obstructive sleep apnea
MX2020010424A (es) * 2018-04-03 2021-01-15 Pure Green Pharmaceuticals Inc Comprimido o composicion que contiene n-acil etanolamina y cannabinoides.
WO2020160452A1 (en) * 2019-02-01 2020-08-06 Tess Ventures, Inc. Combining serms, sarms, and cannabinoids for improving safety and efficacy of endocrine therapies
WO2020214569A1 (en) 2019-04-15 2020-10-22 Metagenics, Inc. Novel hemp and pea formulation and its use
US20220211647A1 (en) * 2019-04-23 2022-07-07 SciSparc Ltd. Compositions and methods for potentiating derivatives of 4-aminophenols
WO2020227440A1 (en) * 2019-05-07 2020-11-12 Ojai Energetics Pbc Methods for optimized cannabinoid dosage determination
WO2020237247A1 (en) 2019-05-23 2020-11-26 India Globalization Capital, Inc. Compositions and methods using cannabinoids for treating stammering/stutering and symptoms of tourette syndrome
EP4017486A4 (en) * 2019-08-19 2023-09-20 Buzzelet Development And Technologies Ltd COMPOSITIONS FOR THE TREATMENT OF A CONDITION CHARACTERIZED BY ANANDAMIDE DEFICIENCY AND THEIR USES
EP3838346A1 (en) * 2019-12-20 2021-06-23 Chemo Research SL Soft gelatin capsules comprising palmitoylethanolamide and alpha-lipoic acid
CN115297854A (zh) 2020-01-10 2022-11-04 帕西拉制药股份有限公司 通过蛛网膜下腔给予缓释脂质体麻醉组合物治疗疼痛
WO2021141959A1 (en) 2020-01-10 2021-07-15 Pacira Pharmaceuticals, Inc. Treatment of pain by administration of sustained-release liposomal anesthetic compositions
US11273122B2 (en) 2020-02-11 2022-03-15 Therese Mainella Combination of cannabis, derivatives thereof and additives in oral care compositions
EP4274573A4 (en) 2021-01-11 2024-12-11 Pacira Pharmaceuticals, Inc. TREATMENT OF HIP PAIN WITH LIPOSOMAL SUSTAINED-RELEASE ANESTHESIA COMPOSITIONS
US20230000936A1 (en) * 2021-06-30 2023-01-05 Demetrix, Inc. Alleviation of itching sensations using cannabinoid compounds
WO2023039419A2 (en) 2021-09-08 2023-03-16 Plantible Foods Inc. Systems and methods for measuring mat density of aquatic biomass
WO2023200906A1 (en) 2022-04-12 2023-10-19 Shackelford Pharma Inc. Treatment of seizure disorders
US12226610B2 (en) 2022-11-03 2025-02-18 Pacira Pharmaceuticals, Inc. Treatment of pain associated with total knee arthroplasty with sustained-release liposomal anesthetic compositions
US11918565B1 (en) 2022-11-03 2024-03-05 Pacira Pharmaceuticals, Inc. Treatment of post-operative pain via sciatic nerve block with sustained-release liposomal anesthetic compositions
WO2024124354A1 (en) * 2022-12-16 2024-06-20 Aima Inc. Compositions and methods for treating or preventing pain or other disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103826621A (zh) * 2011-09-29 2014-05-28 Gw药品有限公司 包含植物大麻素次大麻二酚(cbdv)和大麻二酚(cbd)的药物组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU776414B2 (en) * 1998-05-29 2004-09-09 Neurosciences Research Foundation, Inc. Control of pain with endogenous cannabinoids
US6949582B1 (en) * 1999-05-27 2005-09-27 Wallace Walter H Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment
GB2394894B (en) * 2002-11-04 2005-08-31 G W Pharma Ltd New use for pharmaceutical composition
US20090054526A1 (en) * 2005-07-14 2009-02-26 Hansen Harald S Inhibitors of anorexic lipid hydrolysis for the treatment of eating disorders
GB2432312A (en) * 2005-11-01 2007-05-23 Gw Pharma Ltd Pharmaceutical compositions for the treatment of pain
PL2475352T5 (pl) * 2009-09-07 2019-02-28 Epitech Group S.P.A. Kompozycja zawierająca palmitoiloetanoloamid poddany ultramikronizacji
AT509000B1 (de) * 2009-10-23 2012-12-15 Rausch Peter Wasserlösliche zubereitungen von cannabinoiden und cannabispräparaten und deren anwendungen
EP2719375A1 (en) * 2012-10-10 2014-04-16 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Cannabinoids for the treatment of cancers dependent on hedgehog mechanisms
PL3288553T3 (pl) * 2015-04-29 2023-03-20 Scisparc Ltd Połączenia kannabinoidów i n-acyloetanoloamin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103826621A (zh) * 2011-09-29 2014-05-28 Gw药品有限公司 包含植物大麻素次大麻二酚(cbdv)和大麻二酚(cbd)的药物组合物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
COPPOLA, M ET AL.: "Palmitoylethanolamide: From endogenous cannabimimetic substance to innovative medicine for the treatment of cannabis dependence", 《MEDICAL HYPOTHESES》, vol. 81, no. 4, 31 October 2013 (2013-10-31), pages 619 - 622, XP028713525, DOI: 10.1016/j.mehy.2013.07.016 *
KIRSTEN R MU¨LLER-VAHL ET AL: "Treatment of Tourette syndrome with delta-9-tetrahydrocannabinol (DELTA9-THC): No influence on neuropsychological performance", 《NEUROPSYCHOPHARMACOLOGY》, vol. 28, no. 2, 28 February 2003 (2003-02-28), pages 384 - 388, XP055326007, DOI: 10.1038/sj.npp.1300047 *
PRISMIC PHARMACEUTICALS, INC: "THC and Opiates："entourage effect "of prismic’s IP-ptotected palmitoylethanolamide drives new prescription drug strategy", pages 2, Retrieved from the Internet <URL:https://www.prnewswire.com/news-releases/thc-and-opiates-entourage-effect-of-prismics-ip-protected-palmitoylethanolamide-drives-new-prescription-drug-strategy-300029806.html> *
刘胜等: "《精神外科学基础与临床》", 31 May 1999, 珠海出版社, pages: 146 - 147 *

Also Published As

Publication number Publication date
US20200038367A1 (en) 2020-02-06
CN107530317A (zh) 2018-01-02
EP3288553A4 (en) 2018-12-26
WO2016174661A1 (en) 2016-11-03
CA2984088A1 (en) 2016-11-03
IL291864A (en) 2022-06-01
US11197845B2 (en) 2021-12-14
US20180078523A1 (en) 2018-03-22
AU2023251426A1 (en) 2023-11-09
AU2023251426B2 (en) 2025-11-27
MA41997A (fr) 2021-03-31
EP4193993A3 (en) 2023-07-19
US20200030281A1 (en) 2020-01-30
ES2935605T3 (es) 2023-03-08
US20220071948A1 (en) 2022-03-10
JP2021107401A (ja) 2021-07-29
AU2021206784B2 (en) 2023-07-20
US11234956B2 (en) 2022-02-01
JP6938465B2 (ja) 2021-09-22
JP2018514589A (ja) 2018-06-07
IL255238B (en) 2022-05-01
AU2021206784A1 (en) 2021-08-12
EP4193993A2 (en) 2023-06-14
US11207290B2 (en) 2021-12-28
EP3288553B1 (en) 2022-12-28
DK3288553T3 (da) 2023-01-23
EP3288553A1 (en) 2018-03-07
CA2984088C (en) 2024-04-09
US20210393577A1 (en) 2021-12-23
PL3288553T3 (pl) 2023-03-20
AU2016254685B2 (en) 2021-04-22
AU2016254685A1 (en) 2017-11-09
US20220071949A1 (en) 2022-03-10
IL255238A0 (en) 2017-12-31
US20200022946A1 (en) 2020-01-23

Similar Documents

Publication Publication Date Title
AU2023251426B2 (en) Combinations of cannabinoids and N-acylethanolamines
US20230270690A1 (en) Oral compositions
TWI638654B (zh) 用以治療中樞神經系統疾病之包含苯甲酸鹽化合物及鞣酸的組合物
KR102624627B1 (ko) 지연 방출 데페리프론 정제 및 그의 사용 방법
WO2011085331A1 (en) Methods of providing weight loss therapy in patients with major depression
WO2019130215A1 (en) Cannabis compositions for the treatment of inflammatory skin disorders
JP2022522819A (ja) 疾患の治療のためのロイシン、アセチルロイシン、及び関連類似体
AU2019354784B2 (en) Biphenyl sulfonamide compounds for the treatment of type IV collagen diseases
RU2418601C2 (ru) Средство, обладающее гепатопротекторным, детоксицирующим и регенерирующим действием
US20130012483A1 (en) Novel pharmaceutical composition for the treatment of neurodegenerative or neurovascular diseases
CN116808038A (zh) 阿片类物质和n-酰基乙醇胺的组合
JP6084931B2 (ja) ストレス又は急性聴力損失に関連する耳鳴の治療又は予防のためのネラメキサン
TWI852041B (zh) 採用長春西汀治療近視的方法
HK40085288A (en) Combinations of cannabinoids and n-acylethanolamines
EP1900378A1 (en) Pharmaceutical compositions for the treatment of fungal infections
DE10359790A1 (de) Brausezubereitung einer basischen arzneilich wirksamen Substanz
AU2003238399A1 (en) Use of levocetirizine for the treatment of persistent allergic rhinitis
HK40060739A (en) Compositions and methods for potentiating derivatives of 4-aminophenols
CN113747888A (zh) 用于增强4-氨基苯酚衍生物的组合物和方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20251228

Address after: British Columbia, Canada

Applicant after: Neurotherapy Laboratory Co.

Country or region after: Canada

Address before: Israel Tel Aviv

Applicant before: Sespak Co.,Ltd.

Country or region before: Israel